secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0000950170-24-030776
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01, 2.05, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences reports CAHmelia-203 fails primary endpoint; cuts 21% workforce
--------------------------------------------------------------------------------

- CAHmelia-203 failed primary endpoint; tildacerfont 200mg QD showed -2.6% placebo-adjusted A4 reduction (non-significant).
- Board approved workforce reduction of ~21% and termination of CAHmelia-203; estimated $0.4M cash charges, Q2 2024.
- Pediatric CAHptain-205: 73% of patients met A4 or GC reduction endpoint; more rapid clearance than adults.
- Cash and equivalents $96.3M at Dec 31, 2023; cost reductions extend runway through end of 2025.
- Expects topline CAHmelia-204 in Q3 2024, additional CAHptain-205 data in Q4 2024, FDA meeting in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024030776/0000950170-24-030776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024030776/sprb-20240310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-030776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer